Perrigo Company plc Cost of Revenue
Perrigo Company plc (PRGO) reported Cost of Revenue of $708.90 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- Perrigo Company plc cost of goods and services sold for the quarter ending 2026-06-27 was $708.90M, a 2.24% increase year-over-year.
- Perrigo Company plc cost of goods and services sold for the quarter ending 2026-03-28 was $643.70M, a 1.21% decline year-over-year.
- Perrigo Company plc cost of goods and services sold for the quarter ending 2025-12-31 was $747.40M, a 0.66% decline year-over-year.
- Perrigo Company plc cost of goods and services sold for the quarter ending 2025-09-27 was $666.20M, a 2.47% decline year-over-year.
- Perrigo Company plc cost of goods and services sold for fiscal 2025 was $2.76B, a 2.55% decline from fiscal 2024.
- Perrigo Company plc cost of goods and services sold for fiscal 2024 was $2.83B, a 4.86% decline from fiscal 2023.
- Perrigo Company plc cost of goods and services sold for fiscal 2023 was $2.98B, a 0.70% decline from fiscal 2022.
- Perrigo Company plc cost of goods and services sold for fiscal 2022 was $3.00B, a 10.05% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $708.90M 10-Q · filed 2026-08-05 | $1.35B 10-Q · filed 2026-08-05 | $2.10B derived: sum of 3 quarters · filed 2026-08-05 | $2.77B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-28 | $643.70M 10-Q · filed 2026-05-06 | $1.39B derived: sum of 2 quarters · filed 2026-05-06 | $2.06B derived: sum of 3 quarters · filed 2026-05-06 | $2.75B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $747.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.41B derived: sum of 2 quarters · filed 2026-02-26 | $2.11B derived: sum of 3 quarters · filed 2026-08-05 | $2.76B 10-K · filed 2026-02-26 | ||||
| 2025-09-27 | $666.20M 10-Q · filed 2025-11-05 | $1.36B derived: sum of 2 quarters · filed 2026-08-05 | $2.01B 10-Q · filed 2025-11-05 | $2.76B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-28 | $693.40M 10-Q · filed 2026-08-05 | $1.34B 10-Q · filed 2026-08-05 | $2.10B derived: sum of 3 quarters · filed 2026-08-05 | $2.78B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-29 | $651.60M 10-Q · filed 2026-05-06 | $1.40B derived: sum of 2 quarters · filed 2026-05-06 | $2.09B derived: sum of 3 quarters · filed 2026-05-06 | $2.76B derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $752.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.44B derived: sum of 2 quarters · filed 2026-02-26 | $2.11B derived: sum of 3 quarters · filed 2026-02-26 | $2.83B 10-K · filed 2026-02-26 | ||||
| 2024-09-28 | $683.10M 10-Q · filed 2025-11-05 | $1.35B derived: sum of 2 quarters · filed 2025-11-05 | $2.08B 10-Q · filed 2025-11-05 | $2.81B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-29 | $670.80M 10-Q · filed 2025-08-06 | $1.40B 10-Q · filed 2025-08-06 | $2.12B derived: sum of 3 quarters · filed 2026-02-26 | $2.84B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-30 | $724.40M 10-Q · filed 2025-05-07 | $1.45B derived: sum of 2 quarters · filed 2026-02-26 | $2.17B derived: sum of 3 quarters · filed 2026-02-26 | $2.93B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $729.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.44B derived: sum of 2 quarters · filed 2026-02-26 | $2.21B derived: sum of 3 quarters · filed 2026-02-26 | $2.98B 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $712.60M 10-Q · filed 2024-11-06 | $1.48B derived: sum of 2 quarters · filed 2024-11-06 | $2.25B 10-Q · filed 2024-11-06 | $3.02B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-07-01 | $765.10M 10-Q · filed 2024-08-02 | $1.53B 10-Q · filed 2024-08-02 | $2.31B derived: sum of 3 quarters · filed 2025-02-28 | $3.04B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-04-01 | $767.90M 10-Q · filed 2024-05-07 | $1.54B derived: sum of 2 quarters · filed 2025-02-28 | $2.28B derived: sum of 3 quarters · filed 2025-02-28 | $3.03B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $772.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.51B derived: sum of 2 quarters · filed 2025-02-28 | $2.26B derived: sum of 3 quarters · filed 2025-02-28 | $3.00B 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $737.30M 10-Q · filed 2023-11-07 | $1.49B derived: sum of 2 quarters · filed 2023-11-07 | $2.22B 10-Q · filed 2023-11-07 | $2.97B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-07-02 | $749.60M 10-Q · filed 2023-08-08 | $1.49B 10-Q · filed 2023-08-08 | $2.23B derived: sum of 3 quarters · filed 2024-02-27 | $2.94B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-04-02 | $736.70M 10-Q · filed 2023-05-09 | $1.48B derived: sum of 2 quarters · filed 2024-02-27 | $2.19B derived: sum of 3 quarters · filed 2024-02-27 | $2.82B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $742.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.45B derived: sum of 2 quarters · filed 2024-02-27 | $2.08B derived: sum of 3 quarters · filed 2024-02-27 | $2.72B 10-K · filed 2024-02-27 | ||||
| 2021-10-02 | $706.30M 10-Q · filed 2022-11-08 | $1.34B derived: sum of 2 quarters · filed 2022-11-08 | $1.98B 10-Q · filed 2022-11-08 | $2.65B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-07-03 | $632.10M 10-Q · filed 2022-08-09 | $1.27B 10-Q · filed 2022-08-09 | $1.94B derived: sum of 3 quarters · filed 2023-02-28 | $2.58B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-04-03 | $641.60M 10-Q · filed 2022-05-11 | $1.31B derived: sum of 2 quarters · filed 2023-02-28 | $1.94B derived: sum of 3 quarters · filed 2023-02-28 | $2.55B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $668.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.30B derived: sum of 2 quarters · filed 2023-02-28 | $1.90B derived: sum of 3 quarters · filed 2023-02-28 | $2.59B 10-K · filed 2023-02-28 | $3.25B 10-K · filed 2021-03-01 | |||
| 2020-09-26 | $633.30M 10-Q · filed 2021-11-12 | $785.60M 10-Q · filed 2020-11-05 | $1.23B derived: sum of 2 quarters · filed 2021-11-12 | $1.92B 10-Q · filed 2021-11-12 | $2.43B 10-Q · filed 2020-11-05 | $2.14B derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-27 | $601.60M 10-Q · filed 2021-08-11 | $784.40M 10-Q · filed 2020-08-05 | $1.29B 10-Q · filed 2021-08-11 | $1.64B 10-Q · filed 2020-08-05 | $1.51B derived: sum of 3 quarters · filed 2022-03-01 | $2.28B derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-28 | $689.60M 10-Q · filed 2021-05-12 | $857.80M 10-Q · filed 2020-05-05 | $903.70M derived: sum of 2 quarters · filed 2022-03-01 | $1.68B derived: sum of 3 quarters · filed 2022-03-01 | $2.40B derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $214.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $992.40M derived: sum of 2 quarters · filed 2022-03-01 | $1.71B derived: sum of 3 quarters · filed 2022-03-01 | $2.44B 10-K · filed 2022-03-01 | $3.06B 10-K · filed 2020-02-27 | |||
| 2019-09-28 | $778.30M 10-Q · filed 2020-11-05 | $1.50B derived: sum of 2 quarters · filed 2020-11-05 | $2.22B 10-Q · filed 2020-11-05 | $2.97B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-29 | $718.20M 10-Q · filed 2020-08-05 | $1.44B 10-Q · filed 2020-08-05 | $2.20B derived: sum of 3 quarters · filed 2021-03-01 | $2.90B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-30 | $725.70M 10-Q · filed 2020-05-05 | $1.48B derived: sum of 2 quarters · filed 2021-03-01 | $2.19B derived: sum of 3 quarters · filed 2021-03-01 | $2.90B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $752.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.46B derived: sum of 2 quarters · filed 2021-03-01 | $2.18B derived: sum of 3 quarters · filed 2021-03-01 | $2.90B 10-K · filed 2021-03-01 | ||||
| 2018-09-29 | $708.30M 10-Q · filed 2019-11-06 | $1.42B derived: sum of 2 quarters · filed 2019-11-06 | $2.15B 10-Q · filed 2019-11-06 | $2.92B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $715.40M 10-Q · filed 2019-08-08 | $1.44B 10-Q · filed 2019-08-08 | $2.21B derived: sum of 3 quarters · filed 2020-02-27 | $2.94B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $724.30M 10-Q · filed 2019-05-09 | $1.49B derived: sum of 2 quarters · filed 2020-02-27 | $2.23B derived: sum of 3 quarters · filed 2020-02-27 | $2.96B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $770.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.50B derived: sum of 2 quarters · filed 2020-02-27 | $2.24B derived: sum of 3 quarters · filed 2020-02-27 | $2.97B 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $733.50M 10-Q · filed 2018-11-08 | $1.47B derived: sum of 2 quarters · filed 2018-11-08 | $2.20B 10-Q · filed 2018-11-08 | $3.04B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-07-01 | $733.30M 10-Q · filed 2018-08-09 | $1.46B 10-Q · filed 2018-08-09 | $2.31B derived: sum of 3 quarters · filed 2019-02-27 | $3.08B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-04-01 | $729.60M 10-Q · filed 2018-05-08 | $1.57B derived: sum of 2 quarters · filed 2019-02-27 | $2.35B derived: sum of 3 quarters · filed 2019-02-27 | $3.14B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $843.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $1.62B derived: sum of 2 quarters · filed 2019-02-27 | $2.41B derived: sum of 3 quarters · filed 2019-02-27 | $3.23B 10-K · filed 2019-02-27 | ||||
| 2016-10-01 | $777.10M 10-Q · filed 2017-11-09 | $848.60M 10-Q · filed 2016-11-10 | $1.57B derived: sum of 2 quarters · filed 2017-11-09 | $2.39B 10-Q · filed 2017-11-09 | $2.62B 10-Q · filed 2016-11-10 | $3.20B derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-07-02 | $794.00M 10-Q · filed 2017-08-10 | $913.80M 10-Q · filed 2016-08-10 | $1.61B 10-Q · filed 2017-08-10 | $1.77B 10-Q · filed 2016-08-10 | $2.42B derived: sum of 3 quarters · filed 2018-03-01 | $3.16B derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-04-02 | $814.20M 10-Q · filed 2017-05-30 | $860.30M 10-Q · filed 2016-05-16 | $1.63B derived: sum of 2 quarters · filed 2018-03-01 | $2.37B derived: sum of 3 quarters · filed 2018-03-01 | $3.18B derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $815.40M derived: 10-K 6 month − 10-Q/A 3 month · filed 2018-03-01 | $1.55B 10-K · filed 2018-03-01 | $2.37B derived: sum of 3 quarters · filed 2018-03-01 | $2.97B derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-09-26 | $737.90M 10-Q/A · filed 2017-05-23 | $795.90M 10-Q · filed 2015-11-02 | $1.55B derived: sum of 2 quarters · filed 2017-05-23 | $2.15B 10-Q/A · filed 2017-05-23 | $2.37B 10-Q · filed 2016-11-10 | $2.84B derived: sum of 4 quarters · filed 2017-05-23 | ||
| 2015-06-27 | $814.20M 10-Q/A · filed 2017-05-22 | $903.50M 10-Q · filed 2016-08-10 | $1.41B 10-Q/A · filed 2017-05-22 | $1.57B 10-Q · filed 2016-08-10 | $2.10B derived: sum of 3 quarters · filed 2017-05-22 | $2.58B 10-K · filed 2018-03-01 | ||
| 2015-03-28 | $597.80M 10-Q/A · filed 2017-05-22 | $670.30M 10-Q · filed 2015-04-29 | $1.29B derived: sum of 2 quarters · filed 2017-05-22 | $1.99B 10-Q · filed 2015-04-29 | $2.49B derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2014-12-27 | $687.90M 10-Q · filed 2015-02-05 | $1.17B 10-K · filed 2018-03-01 | $1.32B 10-Q · filed 2015-02-05 | $1.89B derived: sum of 3 quarters · filed 2017-05-22 | $2.58B derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2014-09-27 | $629.70M 10-Q · filed 2015-11-02 | $1.21B derived: sum of 2 quarters · filed 2017-05-22 | $1.90B derived: sum of 3 quarters · filed 2017-05-22 | $2.51B derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-06-28 | $577.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $1.27B derived: sum of 2 quarters · filed 2017-05-22 | $1.88B derived: sum of 3 quarters · filed 2017-05-22 | $2.46B 10-K · filed 2017-05-22 | $2.61B 10-K · filed 2014-08-14 | |||
| 2014-03-29 | $689.20M 10-Q · filed 2015-04-29 | $1.31B derived: sum of 2 quarters · filed 2015-04-29 | $1.88B 10-Q · filed 2015-04-29 | $2.50B derived: sum of 4 quarters · filed 2015-04-29 | ||||
| 2013-12-28 | $618.30M 10-Q · filed 2015-02-05 | $1.20B 10-Q · filed 2015-02-05 | $1.81B derived: sum of 3 quarters · filed 2015-02-05 | $2.39B derived: sum of 4 quarters · filed 2015-02-05 | ||||
| 2013-09-28 | $577.10M 8-K · filed 2014-11-20 | $1.19B derived: sum of 2 quarters · filed 2014-11-20 | $1.78B derived: sum of 3 quarters · filed 2014-11-20 | $2.35B derived: sum of 4 quarters · filed 2014-11-20 | ||||
| 2013-06-29 | $611.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-14 | $1.20B derived: sum of 2 quarters · filed 2014-08-14 | $1.78B derived: sum of 3 quarters · filed 2014-08-14 | $2.26B 10-K · filed 2014-08-14 | ||||
| 2013-03-30 | $588.40M 10-Q · filed 2014-05-07 | $1.16B derived: sum of 2 quarters · filed 2014-05-07 | $1.65B 10-Q · filed 2014-05-07 | |||||
| 2012-12-29 | $575.80M 10-Q · filed 2014-02-06 | $1.06B 10-Q · filed 2014-02-06 | ||||||
| 2012-06-30 | $2.08B 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |